Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL957166 | 0.82 | SLC22A12 (0.44) | KMT2ASMN1; SMN2SLC22A12FFAR1 | |
| SCHEMBL1007881 | 0.82 | SLC22A12 (0.44) | KMT2ASMN1; SMN2SLC22A12FFAR1 | |
| SCHEMBL2185411 | 0.81 | MAPK1 (0.41) | L3MBTL1HTTKMT2ASMN1; SMN2SLC22A12 | |
| SCHEMBL5035708 | 0.80 | F10 (0.44) | L3MBTL1HTTKMT2ASMN1; SMN2SLC22A12 | |
| SCHEMBL3447800 | 0.80 | MAPK1 (0.46) | KMT2ASMN1; SMN2SLC22A12 | |
| SCHEMBL27553225 | 0.80 | L3MBTL1 (0.77) | L3MBTL1AOC3 | |
| SCHEMBL27553226 | 0.80 | L3MBTL1 (0.77) | L3MBTL1AOC3 | |
| SCHEMBL2088936 | 0.79 | MAPK1 (0.42) | HTTKMT2ASMN1; SMN2 | |
| SCHEMBL954605 | 0.78 | PTGS1 (0.58) | KMT2ASMN1; SMN2SLC22A12FFAR1 | |
| SCHEMBL2745203 | 0.78 | PTGS1 (0.58) | KMT2ASMN1; SMN2SLC22A12FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1976377-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2008-10-08 | — | — | EP | claimed |
| WO-2007087505-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-08-02 | — | — | WO | claimed |